OXLUMO Trademark
OXLUMO is a USPTO trademark filed by Alnylam Pharmaceuticals, Inc.. Status: Registered.
Prosecution Summary
Trademark Summary
The mark OXLUMO consists of the stylized word OXLUMO with a design of three hexagonal shapes in different sizes and shadings, covering pharmaceutical preparations for the treatment of primary hyperoxaluria in class 005, along with goods and services in classes 006, 018, 044, 046, 051, and 052. It is owned by Alnylam Pharmaceuticals, Inc., a Delaware corporation based in Cambridge, Massachusetts. The mark is registered on the Principal Register since March 9, 2021, with first use in commerce on December 17, 2020; a security interest has been assigned to Bank of America, N.A. as of October 1, 2025.
Recent Activity
Filed on August 13, 2019, the application was published for opposition on October 15, 2019, followed by notic
Trademark Facts
| Mark | OXLUMO |
|---|---|
| Serial Number | 88576813 |
| Registration Number | 6290281 |
| Status | Registered |
| Filing Date | 2019-08-13 |
| Registration Date | 2021-03-09 |
| Mark Type | Combined |
| Nice Classes | 005 (Pharmaceuticals) |
| Owner | Alnylam Pharmaceuticals, Inc. |
| Attorney of Record | Timothy H. Hiebert |
| Prosecution Events | 26 |
| Latest Event | REM1 on 2026-03-09 |
Goods & Services
Pharmaceutical preparations for the treatment of primary hyperoxaluria